These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19954248)

  • 21. Quantitative structure-activity relationship of phenoxyphenyl-methanamine compounds with 5HT2A, SERT, and hERG activities.
    Mente S; Gallaschun R; Schmidt A; Lebel L; Vanase-Frawley M; Fliri A
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6088-92. PubMed ID: 18948001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.
    Souers AJ; Iyengar RR; Judd AS; Beno DW; Gao J; Zhao G; Brune ME; Napier JJ; Mulhern MM; Lynch JK; Freeman JC; Wodka D; Chen CJ; Falls HD; Brodjian S; Dayton BD; Diaz GJ; Bush EN; Shapiro R; Droz BA; Knourek-Segel V; Hernandez LE; Marsh KC; Reilly RM; Sham HL; Collins CA; Kym PR
    Bioorg Med Chem Lett; 2007 Feb; 17(4):884-9. PubMed ID: 17188866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palladium-catalyzed cross-coupling reactions on a bromo-naphthalene scaffold in the search for novel human CC chemokine receptor 8 (CCR8) antagonists.
    Verhaegen Y; Liu L; Nguyen TT; Van Loy T; Voet ARD; Schols D; Dehaen W; De Jonghe S
    Bioorg Chem; 2021 Feb; 107():104560. PubMed ID: 33383325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds.
    Nisius B; Göller AH; Bajorath J
    Chem Biol Drug Des; 2009 Jan; 73(1):17-25. PubMed ID: 19152631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships and identification of optmized CC-chemokine receptor CCR1, 5, and 8 metal-ion chelators.
    Chalikiopoulos A; Thiele S; Malmgaard-Clausen M; Rydberg P; Isberg V; Ulven T; Frimurer TM; Rosenkilde MM; Gloriam DE
    J Chem Inf Model; 2013 Nov; 53(11):2863-73. PubMed ID: 24083637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative structure-activity relationship models for predicting biological properties, developed by combining structure- and ligand-based approaches: an application to the human ether-a-go-go-related gene potassium channel inhibition.
    Coi A; Massarelli I; Saraceno M; Carli N; Testai L; Calderone V; Bianucci AM
    Chem Biol Drug Des; 2009 Oct; 74(4):416-33. PubMed ID: 19751420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8.
    Jenkins TJ; Guan B; Dai M; Li G; Lightburn TE; Huang S; Freeze BS; Burdi DF; Jacutin-Porte S; Bennett R; Chen W; Minor C; Ghosh S; Blackburn C; Gigstad KM; Jones M; Kolbeck R; Yin W; Smith S; Cardillo D; Ocain TD; Harriman GC
    J Med Chem; 2007 Feb; 50(3):566-84. PubMed ID: 17266208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for computer-aided chemical biology. Part 4: selectivity searching for ion channel ligands and mapping of molecular fragments as selectivity markers.
    Ahmed HE; Geppert H; Stumpfe D; Lounkine E; Bajorath J
    Chem Biol Drug Des; 2009 Mar; 73(3):273-82. PubMed ID: 19207462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.
    Rummel PC; Arfelt KN; Baumann L; Jenkins TJ; Thiele S; Lüttichau HR; Johnsen A; Pease J; Ghosh S; Kolbeck R; Rosenkilde MM
    Br J Pharmacol; 2012 Nov; 167(6):1206-17. PubMed ID: 22708643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity.
    Lewis DF; Ito Y
    Xenobiotica; 2009 Aug; 39(8):625-35. PubMed ID: 19514836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classification models for HERG inhibitors by counter-propagation neural networks.
    Thai KM; Ecker GF
    Chem Biol Drug Des; 2008 Oct; 72(4):279-89. PubMed ID: 18844674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.
    Cherney RJ; Mo R; Meyer DT; Nelson DJ; Lo YC; Yang G; Scherle PA; Mandlekar S; Wasserman ZR; Jezak H; Solomon KA; Tebben AJ; Carter PH; Decicco CP
    J Med Chem; 2008 Feb; 51(4):721-4. PubMed ID: 18232650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chapter 8. Activation mechanisms of chemokine receptors.
    Jensen PC; Rosenkilde MM
    Methods Enzymol; 2009; 461():171-90. PubMed ID: 19480919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
    Suzuki T; Kameda M; Ando M; Miyazoe H; Sekino E; Ito S; Masutani K; Kamijo K; Takezawa A; Moriya M; Ito M; Ito J; Nakase K; Matsushita H; Ishihara A; Takenaga N; Tokita S; Kanatani A; Sato N; Fukami T
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5339-45. PubMed ID: 19683441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemokine receptor antagonists: part 2.
    Pease JE; Horuk R
    Expert Opin Ther Pat; 2009 Feb; 19(2):199-221. PubMed ID: 19441918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
    Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
    Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxazolidinones as novel human CCR8 antagonists.
    Jin J; Wang Y; Wang F; Kerns JK; Vinader VM; Hancock AP; Lindon MJ; Stevenson GI; Morrow DM; Rao P; Nguyen C; Barrett VJ; Browning C; Hartmann G; Andrew DP; Sarau HM; Foley JJ; Jurewicz AJ; Fornwald JA; Harker AJ; Moore ML; Rivero RA; Belmonte KE; Connor HE
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1722-5. PubMed ID: 17267215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.
    Pruitt JR; Batt DG; Wacker DA; Bostrom LL; Booker SK; McLaughlin E; Houghton GC; Varnes JG; Christ DD; Covington M; Das AM; Davies P; Graden D; Kariv I; Orlovsky Y; Stowell NC; Vaddi KG; Wadman EA; Welch PK; Yeleswaram S; Solomon KA; Newton RC; Decicco CP; Carter PH; Ko SS
    Bioorg Med Chem Lett; 2007 Jun; 17(11):2992-7. PubMed ID: 17418570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites.
    Zürcher M; Diederich F
    J Org Chem; 2008 Jun; 73(12):4345-61. PubMed ID: 18510366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
    J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.